ArticleNeurological research and practice2023

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.

Niklas Grassl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.